The Star-Ledger - NJ.com
Stock Investors Sell Off Shares of Bristol-Myers Squibb, Down 3.6%
Financial News Network Online
The Company's products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders. There is potential upside of 4.3% for shares of Bristol-Myers ...
Bristol-Myers Squibb Higher Ahead of Earnings
CITIGROUP RAISED ITS PT FOR BRISTOL-MYERS SQUIBB TO $40 (BMY)